NEVVI Medicare utilization intelligence
or

← back

Provider profile

KODITYAL, SANDEEP MD

Hematology-Oncology · NPI 1790820736 · SHENANDOAH, TX

1
Groups
24
Codes · 2024
22,680
Disclosed services

KODITYAL, SANDEEP is a Hematology-Oncology in SHENANDOAH, TX, a member of 1 medical group, who billed 24 distinct codes to Medicare Part B in 2024.

Groups: AMERICAN ONCOLOGY PARTNERS PA (FORT WAYNE, IN)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

22,680
disclosed services
24
codes billed to Medicare Part B
Prior year · CY2023 50,021 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1756 Injection, iron sucrose, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2919 Injection, methylprednisolone sodium succinate, 5 mg
36415 Insertion of needle into vein for collection of blood sample
88185 Flow cytometry technique for dna or cell analysis, each additional marker
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
96372 Injection of drug or substance under skin or into muscle
96413 Administration of chemotherapy into vein, 1 hour or less
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96375 Injection of additional new drug or substance into vein
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99443 Telephone medical discussion with physician, 21-30 minutes
96415 Administration of chemotherapy into vein, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
88184 Flow cytometry technique for dna or cell analysis, first marker
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
99442 Telephone medical discussion with physician, 11-20 minutes
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.